Companies ›Healthcare ›ANUH.NS

ANUH.NS — NSE (India) Pharmaceuticals

Anuh.Ns

$78,59

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

1,85 %

Op margin

8,3 %

ROE

14,5 %

Net margin

7,2 %

Debt / equity

0,03

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

ANUH.NS operates in the pharmaceuticals industry, generating revenue primarily through the development, manufacturing, and sale of pharmaceutical products.

Business. ANUH.NS operates in the pharmaceuticals industry, generating revenue primarily through the development, manufacturing, and sale of pharmaceutical products.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

ActivityPharmaceuticals & Medical Research

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

14,5 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning ANUH.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to ANUH.NS. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

ANUH.NS operates in the pharmaceuticals industry, generating revenue primarily through the development, manufacturing, and sale of pharmaceutical products.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

ActivityPharmaceuticals & Medical Research

AI synthesis

GENERATED

ANUH.NS maintains a strong liquidity position, with a current ratio of 2.11, indicating the company can cover its short-term liabilities more than twice over with its current assets. The company's liquidity_fpt score suggests a medium liquidity risk, which is consistent with its cash flow generation and asset composition. Free cash flow of INR 234.23 million supports operational flexibility and potential reinvestment.

Profitability metrics show a return on equity (ROE) of 14.52% and a return on assets (ROA) of 9.35%, both of which are strong indicators of efficient capital use and asset management. These figures are well above the typical thresholds for the pharmaceutical industry, suggesting ANUH.NS is outperforming its peers in terms of capital returns.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financial data. This lack of segment or geographic diversification may increase exposure to regional economic or regulatory shifts.

Looking ahead, ANUH.NS is projected to maintain a stable growth trajectory, with no significant revenue deltas expected in the current or next fiscal year. Historical revenue growth has been steady, but the absence of disclosed new product launches or market expansion plans suggests a conservative growth strategy.

Risk factors include a medium liquidity risk and a low dilution potential, with no significant dilution events reported in the latest filings. The company's debt-to-equity ratio of 0.03 indicates a conservative capital structure, with minimal reliance on debt financing. However, the company has a negative net cash position after subtracting total debt, which could limit its ability to respond to unexpected capital needs.

Recent events include the filing of the latest financial statements, which show consistent performance in operating income and net income. No material changes in business strategy or regulatory environment have been disclosed in the latest filings.

Key takeaways

ANUH.NS has a strong liquidity position with a current ratio of 2.11.
The company's ROE of 14.52% and ROA of 9.35% indicate efficient capital and asset use.
Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
The company maintains a conservative capital structure with a low debt-to-equity ratio of 0.03.
No significant dilution events are expected in the near term.
Growth is projected to remain stable, with no major revenue deltas anticipated.

Bull / Bear case

analysis pipeline

— missing data

In focus — financials by report

Valuation

Market price

$78,59

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$3.26B

Net cashⓘ

-$108.9M

Current ratioⓘ

2.1

Debt / equityⓘ

0.0

ROAⓘ

9.3%

ROEⓘ

14.5%

Cash conversionⓘ

78.0%

CapEx / revenueⓘ

-3.0%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin8,3 %Above median

Net Margin7,2 %Above median

ROE14,5 %Above P75

Capex / Rev-3,0 %Above median

D/E0,03Above median

Cash Conv0,78Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

ANUH.NS Market data — financials · 2026-05-27

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

ANUH.NSCanonical

NSE (India) · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread